<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39337246</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Protective Role of Interleukin-37 in Cardiovascular Diseases through Ferroptosis Modulation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9758</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25189758</ELocationID><Abstract><AbstractText>The role of ferroptosis and iron metabolism dysregulation in the pathophysiology of cardiovascular diseases is increasingly recognized. Conditions such as hypertension, cardiomyopathy, atherosclerosis, myocardial ischemia/reperfusion injury, heart failure, and cardiovascular complications associated with COVID-19 have been linked to these processes. Inflammation is central to these conditions, prompting exploration into the inflammatory and immunoregulatory molecular pathways that mediate ferroptosis and its contribution to cardiovascular disease progression. Notably, emerging evidence highlights interleukin-37 as a protective cytokine with the ability to activate the nuclear factor erythroid 2-related factor 2 pathway, inhibit macrophage ferroptosis, and attenuate atherosclerosis progression in murine models. However, a comprehensive review focusing on interleukin-37 and its protective role against ferroptosis in CVD is currently lacking. This review aims to fill this gap by summarizing existing knowledge on interleukin-37, including its regulatory functions and impact on ferroptosis in conditions such as atherosclerosis and myocardial infarction. We also explore experimental strategies and propose that targeting interleukin-37 to modulate ferroptosis presents a promising therapeutic approach for the prevention and treatment of cardiovascular diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz-Gregorio</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0077-5079</Identifier><AffiliationInfo><Affiliation>Departamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezcua-Guerra</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-6258-5732</Identifier><AffiliationInfo><Affiliation>Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Atención a la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Unidad Xochimilco, Ciudad de México 14387, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher-Bautista</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Maestría en Ciencias Químico Biológicas, Instituto Politécnico Nacional, Ciudad de México 11350, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Beltrán</LastName><ForeName>Abraham</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Atención a la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Unidad Xochimilco, Ciudad de México 14387, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonseca-Camarillo</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7489-2596</Identifier><AffiliationInfo><Affiliation>Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>na</GrantID><Agency>Instituto Nacional de Cardiología Ignacio Chávez</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508587">IL37 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="Y">Interleukin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">ferroptosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">interleukin-37</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337246</ArticleId><ArticleId IdType="pmc">PMC11432013</ArticleId><ArticleId IdType="doi">10.3390/ijms25189758</ArticleId><ArticleId IdType="pii">ijms25189758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie L.H., Fefelova N., Pamarthi S.H., Gwathmey J.K. Molecular Mechanisms of Ferroptosis and Relevance to Cardiovascular Disease. Cells. 2022;11:2726. doi: 10.3390/cells11172726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11172726</ArticleId><ArticleId IdType="pmc">PMC9454912</ArticleId><ArticleId IdType="pubmed">36078133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Li X., Wang S., Miao R., Zhong J. Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases. Nutrients. 2023;15:591. doi: 10.3390/nu15030591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15030591</ArticleId><ArticleId IdType="pmc">PMC9921472</ArticleId><ArticleId IdType="pubmed">36771298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Fan H., Wang S., Tang G., Zhai C., Shen L. Ferroptosis: A Novel Therapeutic Target for Ischemia-Reperfusion Injury. Front. Cell Dev. Biol. 2021;9:688605. doi: 10.3389/fcell.2021.688605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.688605</ArticleId><ArticleId IdType="pmc">PMC8384466</ArticleId><ArticleId IdType="pubmed">34447746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantrell A.C., Zeng H., Chen J.X. The Therapeutic Potential of Targeting Ferroptosis in the Treatment of Mitochondrial Cardiomyopathies and Heart Failure. J. Cardiovasc. Pharmacol. 2024;83:23–32. doi: 10.1097/FJC.0000000000001496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001496</ArticleId><ArticleId IdType="pmc">PMC10843296</ArticleId><ArticleId IdType="pubmed">37816193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T., Wang K., Li Y., Ye Y., Chen Y., Wang J., Yao C. Construction of a Novel Ferroptosis-Related Gene Signature of Atherosclerosis. Front. Cell Dev. Biol. 2022;9:800833. doi: 10.3389/fcell.2021.800833.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.800833</ArticleId><ArticleId IdType="pmc">PMC8766414</ArticleId><ArticleId IdType="pubmed">35071238</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X., Ardehali H., Min J., Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat. Rev. Cardiol. 2023;20:7–23. doi: 10.1038/s41569-022-00735-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-022-00735-4</ArticleId><ArticleId IdType="pmc">PMC9252571</ArticleId><ArticleId IdType="pubmed">35788564</ArticleId></ArticleIdList></Reference><Reference><Citation>Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010;11:1014–1022. doi: 10.1038/ni.1944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1944</ArticleId><ArticleId IdType="pmc">PMC3537119</ArticleId><ArticleId IdType="pubmed">20935647</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Camarillo G., Furuzawa-Carballeda J., Yamamoto-Furusho J.K. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine. 2015;75:389–402. doi: 10.1016/j.cyto.2015.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2015.04.009</ArticleId><ArticleId IdType="pubmed">26141420</ArticleId></ArticleIdList></Reference><Reference><Citation>Law C.C., Puranik R., Fan J., Fei J., Hambly B.D., Bao S. Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19. Front. Cardiovasc. Med. 2021;8:630767. doi: 10.3389/fcvm.2021.630767.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.630767</ArticleId><ArticleId IdType="pmc">PMC8377289</ArticleId><ArticleId IdType="pubmed">34422917</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Han X., Xia N., Zhao Q., Cheng Z. IL-37 suppresses macrophage ferroptosis to attenuate diabetic atherosclerosis via the NRF2 pathway. Exp. Ther. Med. 2023;25:289. doi: 10.3892/etm.2023.11988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2023.11988</ArticleId><ArticleId IdType="pmc">PMC10189585</ArticleId><ArticleId IdType="pubmed">37206550</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–1072. doi: 10.1016/j.cell.2012.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId><ArticleId IdType="pmc">PMC3367386</ArticleId><ArticleId IdType="pubmed">22632970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D., Chen X., Kang R., Kroemer G. Ferroptosis: Molecular mechanisms and health implications. Cell Res. 2021;31:107–125. doi: 10.1038/s41422-020-00441-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId><ArticleId IdType="pmc">PMC8026611</ArticleId><ArticleId IdType="pubmed">33268902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassannia B., Vandenabeele P., Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830–849. doi: 10.1016/j.ccell.2019.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2019.04.002</ArticleId><ArticleId IdType="pubmed">31105042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrera L., Espiritu R.A., Ros U., Weber J., Schmitt A., Stroh J., Hailfinger S., von Karstedt S., García-Sáez A.J. Ferroptotic pores induce Ca2+ fluxes and ESCRT-III activation to modulate cell death kinetics. Cell Death Differ. 2021;28:1644–1657. doi: 10.1038/s41418-020-00691-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00691-x</ArticleId><ArticleId IdType="pmc">PMC8167089</ArticleId><ArticleId IdType="pubmed">33335287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Stockwell B.R., Conrad M. Ferroptosis: Mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 2021;22:266–282. doi: 10.1038/s41580-020-00324-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-00324-8</ArticleId><ArticleId IdType="pmc">PMC8142022</ArticleId><ArticleId IdType="pubmed">33495651</ArticleId></ArticleIdList></Reference><Reference><Citation>Björkegren J.L.M., Lusis A.J. Atherosclerosis: Recent developments. Cell. 2022;185:1630–1645. doi: 10.1016/j.cell.2022.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9119695</ArticleId><ArticleId IdType="pubmed">35504280</ArticleId></ArticleIdList></Reference><Reference><Citation>You J., Ouyang S., Xie Z., Zhi C., Yu J., Tan X., Li P., Lin X., Ma W., Liu Z., et al. The suppression of hyperlipid diet-induced ferroptosis of vascular smooth muscle cells protests against atherosclerosis independent of p53/SCL7A11/GPX4 axis. J. Cell. Physiol. 2023;238:1891–1908. doi: 10.1002/jcp.31045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.31045</ArticleId><ArticleId IdType="pubmed">37269460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W.S., Stockwell B.R. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016;26:165–176. doi: 10.1016/j.tcb.2015.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId><ArticleId IdType="pmc">PMC4764384</ArticleId><ArticleId IdType="pubmed">26653790</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesfay L., Paul B.T., Konstorum A., Deng Z., Cox A.O., Lee J., Furdui C.M., Hegde P., Torti F.M., Torti S.V. Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death. Cancer Res. 2019;79:5355–5366. doi: 10.1158/0008-5472.CAN-19-0369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-19-0369</ArticleId><ArticleId IdType="pmc">PMC6801059</ArticleId><ArticleId IdType="pubmed">31270077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Ma Y., Lv G., Wang H. Ferroptosis as a therapeutic target for inflammation-related intestinal diseases. Front. Pharmacol. 2023;14:1095366. doi: 10.3389/fphar.2023.1095366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1095366</ArticleId><ArticleId IdType="pmc">PMC9880170</ArticleId><ArticleId IdType="pubmed">36713828</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435. doi: 10.1038/nature07201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07201</ArticleId><ArticleId IdType="pubmed">18650913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocansey D.K.W., Yuan J., Wei Z., Mao F., Zhang Z. Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease. Int. J. Mol. Med. 2023;51:53. doi: 10.3892/ijmm.2023.5256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2023.5256</ArticleId><ArticleId IdType="pmc">PMC10198063</ArticleId><ArticleId IdType="pubmed">37203397</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioranelli M., Roccia M.G., Flavin D., Cota L. Regulation of Inflammatory Reaction in Health and Disease. Int. J. Mol. Sci. 2021;22:5277. doi: 10.3390/ijms22105277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22105277</ArticleId><ArticleId IdType="pmc">PMC8157220</ArticleId><ArticleId IdType="pubmed">34067872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang J., Li J., Zhu J., Wang R., Xi Q., Wu H., Shi T., Chen W. Astragalus polysaccharide prevents ferroptosis in a murine model of experimental colitis and human Caco-2 cells via inhibiting NRF2/HO-1 pathway. Eur. J. Pharmacol. 2021;911:174518. doi: 10.1016/j.ejphar.2021.174518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174518</ArticleId><ArticleId IdType="pubmed">34562468</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Liu Z., Xiao J. Ferroptosis: A Double-Edged Sword in Gastrointestinal Disease. Int. J. Mol. Sci. 2021;22:12403. doi: 10.3390/ijms222212403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212403</ArticleId><ArticleId IdType="pmc">PMC8620748</ArticleId><ArticleId IdType="pubmed">34830285</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi J., Kim J.-W., Zhou Z., Lim C.W., Kim B. Ferroptosis affects the progression of non-alcoholic steatohepatitis via the modulation of lipid peroxidation–mediated cell death in mice. Am. J. Pathol. 2019;190:68–81. doi: 10.1016/j.ajpath.2019.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2019.09.011</ArticleId><ArticleId IdType="pubmed">31610178</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong T., Liu L., Jiang W., Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 2020;20:95–112. doi: 10.1038/s41577-019-0215-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0215-7</ArticleId><ArticleId IdType="pubmed">31558839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Kang R., Tang D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 2022;54:91–102. doi: 10.1038/s12276-022-00736-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00736-w</ArticleId><ArticleId IdType="pmc">PMC8894452</ArticleId><ArticleId IdType="pubmed">35217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Agborbesong E., Li L.X., Li L., Li X. Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD. Front. Mol. Biosci. 2022;9:922428. doi: 10.3389/fmolb.2022.922428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.922428</ArticleId><ArticleId IdType="pmc">PMC9277309</ArticleId><ArticleId IdType="pubmed">35847973</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J., Fulda S., Gascón S., Hatzios S.K., Kagan V.E., et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273–285. doi: 10.1016/j.cell.2017.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId><ArticleId IdType="pmc">PMC5685180</ArticleId><ArticleId IdType="pubmed">28985560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi M., Cotella D., Santoro C., Corà D., Barlev N.A., Piacentini M., Corazzari M. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis. 2019;10:902. doi: 10.1038/s41419-019-2143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-2143-7</ArticleId><ArticleId IdType="pmc">PMC6883066</ArticleId><ArticleId IdType="pubmed">31780644</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.S., Wang S.F., Hsu C.Y., Yin P.H., Yeh T.S., Lee H.C., Tseng L.M. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2α-ATF4 pathway. Oncotarget. 2017;8:114588–114602. doi: 10.18632/oncotarget.23055.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23055</ArticleId><ArticleId IdType="pmc">PMC5777716</ArticleId><ArticleId IdType="pubmed">29383104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Tao J., Yang Y., Tan S., Liu H., Jiang J., Zheng F., Wu B. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis. Cell Death Dis. 2020;11:86. doi: 10.1038/s41419-020-2299-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2299-1</ArticleId><ArticleId IdType="pmc">PMC6997394</ArticleId><ArticleId IdType="pubmed">32015337</ArticleId></ArticleIdList></Reference><Reference><Citation>Colakoglu M., Tuncer S., Banerjee S. Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1. Cell Prolif. 2018;51:e12472. doi: 10.1111/cpr.12472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.12472</ArticleId><ArticleId IdType="pmc">PMC6528901</ArticleId><ArticleId IdType="pubmed">30062726</ArticleId></ArticleIdList></Reference><Reference><Citation>Uauy R., Mena P., Rojas C. Essential fatty acid metabolism in the micropremie. Clin. Perinatol. 2000;27:71–93. doi: 10.1016/S0095-5108(05)70007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0095-5108(05)70007-5</ArticleId><ArticleId IdType="pubmed">10690565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R.I., Benincaso A.I., Knoell C.T., Larkin J.K., Austen K.F., Robinson D.R. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J. Clin. Investig. 1993;91:651–660. doi: 10.1172/JCI116245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI116245</ArticleId><ArticleId IdType="pmc">PMC288002</ArticleId><ArticleId IdType="pubmed">8381824</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge H.W., Dekkers D.H., Lamers J.M. Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. Mol. Cell. Biochem. 1996;157:199–210. doi: 10.1007/BF00227899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00227899</ArticleId><ArticleId IdType="pubmed">8739247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Tang J., Song J., Xie M., Liu Y., Dong Z., Liu X., Li X., Zhang M., Chen Y., et al. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling. Free Radic. Biol. Med. 2022;181:130–142. doi: 10.1016/j.freeradbiomed.2022.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2022.01.020</ArticleId><ArticleId IdType="pubmed">35122997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren F., Yang Y., Wu K., Zhao T., Shi Y., Song M., Li J. The effects of dandelion polysaccharides on iron metabolism by regulating hepcidin via JAK/STAT signaling pathway. Oxidative Med. Cell. Longev. 2021;2021:7184760. doi: 10.1155/2021/7184760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/7184760</ArticleId><ArticleId IdType="pmc">PMC7801049</ArticleId><ArticleId IdType="pubmed">33488942</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam Z., Devalaraja S., Li M., To T.K.J., Folkert I.W., Mitchell-Velasquez E., Dang M.T., Young P., Wilbur C.J., Silverman M.A., et al. Counter regulation of spic by NF-κB and STAT signaling controls inflammation and iron metabolism in macrophages. Cell Rep. 2020;31:107825. doi: 10.1016/j.celrep.2020.107825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107825</ArticleId><ArticleId IdType="pmc">PMC8944937</ArticleId><ArticleId IdType="pubmed">32610126</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Liang Y., Wei T., Zou L., Huang X., Kong L., Tang M., Zhang T. The role of ferroptosis mediated by NRF2/ERK-regulated ferritinophagy in CdTe QDs induced inflammation in macrophage. J. Hazard. Mater. 2022;436:129043. doi: 10.1016/j.jhazmat.2022.129043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhazmat.2022.129043</ArticleId><ArticleId IdType="pubmed">35525219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Ezquerro J.J., Cuenda A. P38 signalling pathway. Int. J. Mol. Sci. 2021;22:1003. doi: 10.3390/ijms22031003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031003</ArticleId><ArticleId IdType="pmc">PMC7863928</ArticleId><ArticleId IdType="pubmed">33498296</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Liu Y., Guo Y., Liu C., Yang Y., Fan X., Yang H., Liu Y., Ma T. Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases. Biochem. Pharmacol. 2024;220:115973. doi: 10.1016/j.bcp.2023.115973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2023.115973</ArticleId><ArticleId IdType="pubmed">38103797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluba-Brzózka A., Franczyk B., Rysz-Górzyńska M., Ławiński J., Rysz J. Emerging Anti-Atherosclerotic Therapies. Int. J. Mol. Sci. 2021;22:12109. doi: 10.3390/ijms222212109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212109</ArticleId><ArticleId IdType="pmc">PMC8624828</ArticleId><ArticleId IdType="pubmed">34829992</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J.-L., Jin X.-K., Zhang S.-M., Huang Q.-X., Ji P., Deng X.-C., Cheng S.-X., Chen W.-H., Zhang X.-Z. Specific activation of cGAS-STING pathway by nanotherapeu-tics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Sci. Bull. 2023;68:622–636. doi: 10.1016/j.scib.2023.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scib.2023.02.027</ArticleId><ArticleId IdType="pubmed">36914548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Liu J., Hou W., Kang R., Tang D. STING1 promotes ferroptosis through MFN1/2-dependent mitochondrial fusion. Front. Cell Dev. Biol. 2021;9:698679. doi: 10.3389/fcell.2021.698679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.698679</ArticleId><ArticleId IdType="pmc">PMC8236825</ArticleId><ArticleId IdType="pubmed">34195205</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillin I., Riteau N. STING Signaling and Sterile Inflammation. Front. Immunol. 2021;12:1–15. doi: 10.3389/fimmu.2021.753789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.753789</ArticleId><ArticleId IdType="pmc">PMC8517477</ArticleId><ArticleId IdType="pubmed">34659260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia M., Qin D., Zhao C., Chai L., Yu Z., Wang W., Tong L., Lv L., Wang Y., Rehwinkel J., et al. Redox homeostasis maintained by GPX4 facilitates STING activation. Nat. Immunol. 2020;21:727–735. doi: 10.1038/s41590-020-0699-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0699-0</ArticleId><ArticleId IdType="pubmed">32541831</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeney V., Eaton J.W., Balla G., Balla J. Natural history of the bruise: Formation, elimination, and biological effects of oxidized hemoglobin. Oxidative Med. Cell. Longev. 2013;2013:9. doi: 10.1155/2013/703571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/703571</ArticleId><ArticleId IdType="pmc">PMC3671564</ArticleId><ArticleId IdType="pubmed">23766858</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares M.P., Bozza M.T. Red alert: Labile heme is an alarmin. Curr. Opin. Immunol. 2016;38:94–100. doi: 10.1016/j.coi.2015.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2015.11.006</ArticleId><ArticleId IdType="pubmed">26741528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang L., Pitzer A.L., Li X., Li P.L., Zhang Y. Contribution of redox-dependent activation of endothelial Nlrp3 in-flammasomes to hyperglycemia-induced endothelial dysfunction. J. Mol. Med. 2016;94:1335–1347. doi: 10.1007/s00109-016-1481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1481-5</ArticleId><ArticleId IdType="pmc">PMC5512566</ArticleId><ArticleId IdType="pubmed">27783111</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdei J., Tóth A., Balogh E., Nyakundi B.B., Bányai E., Ryffel B., Paragh G., Cordero M.D., Jeney V. Induction of NLRP3 Inflammasome Activation by Heme in Human Endothelial Cells. Oxidative Med. Cell. Longev. 2018;2018:4310816. doi: 10.1155/2018/4310816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4310816</ArticleId><ArticleId IdType="pmc">PMC5883980</ArticleId><ArticleId IdType="pubmed">29743981</ArticleId></ArticleIdList></Reference><Reference><Citation>Schillemans M., Karampini E., Kat M., Bierings R. Exocytosis of Weibel-Palade bodies: How to unpack a vascular emergency kit. J. Thromb. Haemost. 2019;17:6–18. doi: 10.1111/jth.14322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14322</ArticleId><ArticleId IdType="pmc">PMC7379738</ArticleId><ArticleId IdType="pubmed">30375718</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcher J.D., Chen C., Nguyen J., Milbauer L., Abdulla F., Alayash A.I., Smith A., Nath K.A., Hebbel R.P., Vercellotti G.M. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123:377–390. doi: 10.1182/blood-2013-04-495887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-04-495887</ArticleId><ArticleId IdType="pmc">PMC3894494</ArticleId><ArticleId IdType="pubmed">24277079</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins R., Knapp S. Heme and hemolysis in innate immunity: Adding insult to injury. Curr. Opin. Immunol. 2018;50:14–20. doi: 10.1016/j.coi.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2017.10.005</ArticleId><ArticleId IdType="pubmed">29107115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Fang Z.M., Yi X., Wei X., Jiang D.S. The interaction between ferroptosis and inflammatory signaling pathways. Cell Death Dis. 2023;14:205. doi: 10.1038/s41419-023-05716-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-05716-0</ArticleId><ArticleId IdType="pmc">PMC10030804</ArticleId><ArticleId IdType="pubmed">36944609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapralov A.A., Yang Q., Dar H.H., Tyurina Y.Y., Anthonymuthu T.S., Kim R., St Croix C.M., Mikulska-Ruminska K., Liu B., Shrivastava I.H., et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol. 2020;16:278–290. doi: 10.1038/s41589-019-0462-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-019-0462-8</ArticleId><ArticleId IdType="pmc">PMC7233108</ArticleId><ArticleId IdType="pubmed">32080625</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Meng F., Huo F., Zhu Y., Qin Y., Gui Y., Zhang H., Lin P., He Q., Li Y., et al. Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1/TLR4/STAT3 axis in M1 macrophages. Redox Biol. 2024;75:103255. doi: 10.1016/j.redox.2024.103255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2024.103255</ArticleId><ArticleId IdType="pmc">PMC11304870</ArticleId><ArticleId IdType="pubmed">39029270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Zhang H., Chen Y., Liu X., Tian J., Shen W. The Role of Macrophage Iron Overload and Ferroptosis in Atherosclerosis. Biomolecules. 2022;12:1702. doi: 10.3390/biom12111702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12111702</ArticleId><ArticleId IdType="pmc">PMC9688033</ArticleId><ArticleId IdType="pubmed">36421722</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques L., Negre-Salvayre A., Costa L., Canonne-Hergaux F. Iron gene expression profile in atherogenic Mox macrophages. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2016;1862:1137–1146. doi: 10.1016/j.bbadis.2016.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.03.004</ArticleId><ArticleId IdType="pubmed">26972048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelissen A., Guo L., Sakamoto A., Virmani R., Finn A.V. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine. 2019;47:598–606. doi: 10.1016/j.ebiom.2019.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.08.014</ArticleId><ArticleId IdType="pmc">PMC6796517</ArticleId><ArticleId IdType="pubmed">31416722</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L., Luo G., Guo X., Jiang C., Zeng H., Zhou F., Li Y., Yu J., Yao P. Macrophage iron retention aggravates atherosclerosis: Evidence for the role of autocrine formation of hepcidin in plaque macrophages. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids. 2020;1865:158531. doi: 10.1016/j.bbalip.2019.158531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2019.158531</ArticleId><ArticleId IdType="pubmed">31666189</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y., Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol. 2016;28:181–188. doi: 10.1093/intimm/dxv063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxv063</ArticleId><ArticleId IdType="pmc">PMC4889878</ArticleId><ArticleId IdType="pubmed">26545932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello C.A., Nold-Petry C., Nold M., Fujita M., Li S., Kim S., Bufler P. Suppression of innate inflammation and immunity by interleukin-37. Eur. J. Immunol. 2016;46:1067–1081. doi: 10.1002/eji.201545828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201545828</ArticleId><ArticleId IdType="pmc">PMC5003108</ArticleId><ArticleId IdType="pubmed">27060871</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W.D., Zhao Y., Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun. Rev. 2015;14:1170–1175. doi: 10.1016/j.autrev.2015.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.006</ArticleId><ArticleId IdType="pubmed">26264940</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirk S., Agrawal D.K. Immunobiology of IL-37: Mechanism of action and clinical perspectives. Expert. Rev. Clin. Immunol. 2014;10:1703–1709. doi: 10.1586/1744666X.2014.971014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/1744666X.2014.971014</ArticleId><ArticleId IdType="pmc">PMC4596230</ArticleId><ArticleId IdType="pubmed">25327443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Hanning C.R., Brigham-Burke M.R., Rieman D.J., Lehr R., Khandekar S., Kirkpatrick R.B., Scott G.F., Lee J.C., Lynch F.J., et al. Interleukin-1F7B (IL-1H4/IL-1 F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 2002;18:61–71. doi: 10.1006/cyto.2002.0873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2002.0873</ArticleId><ArticleId IdType="pubmed">12096920</ArticleId></ArticleIdList></Reference><Reference><Citation>Tete S., Tripodi D., Rosati M., Conti F., Maccauro G., Saggini A., Cianchetti E., Caraffa A., Antinolfi P., Toniato E., et al. IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int. J. Immunopathol. Pharmacol. 2012;25:31–38. doi: 10.1177/039463201202500105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201202500105</ArticleId><ArticleId IdType="pubmed">22507315</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti S., Bozza S., Oikonomou V., Renga G., Casagrande A., Iannitti R.G., Puccetti M., Garlanda C., Kim S., Li S., et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10:e1004462. doi: 10.1371/journal.ppat.1004462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004462</ArticleId><ArticleId IdType="pmc">PMC4223056</ArticleId><ArticleId IdType="pubmed">25375146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan R., Agrawal D.K., Thankam F.G. Treg cells in atherosclerosis. Mol. Biol. Rep. 2021;48:4897–4910. doi: 10.1007/s11033-021-06483-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06483-x</ArticleId><ArticleId IdType="pubmed">34117978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfy H., Moaaz M., Moaaz M. The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis. Vascular. 2020;28:629–642. doi: 10.1177/1708538120921735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1708538120921735</ArticleId><ArticleId IdType="pubmed">32366176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Q., Zeng Q., Huang Y., Shi Y., Lin Y., Lu Z., Meng K., Wu B., Yu K., Chai M., et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014;2014:165742. doi: 10.1155/2014/165742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/165742</ArticleId><ArticleId IdType="pmc">PMC3964842</ArticleId><ArticleId IdType="pubmed">24733959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai M., Ji Q., Zhang H., Zhou Y., Yang Q., Zhou Y., Guo G., Liu W., Han W., Yang L., et al. The Protective Effect of Interleukin-37 on Vascular Calcification and Atherosclerosis in Apolipoprotein E-Deficient Mice with Diabetes. J. Interferon Cytokine Res. 2015;35:530–539. doi: 10.1089/jir.2014.0212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2014.0212</ArticleId><ArticleId IdType="pubmed">25866993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello R.O., Chin V.K., Isnadi M.F.A.R., Majid R.A., Abdullah M.A., Lee T.Y., Zakaria Z.A., Hussain M.K., Basir R. The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis. Int. J. Mol. Sci. 2018;19:1149. doi: 10.3390/ijms19041149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19041149</ArticleId><ArticleId IdType="pmc">PMC5979316</ArticleId><ArticleId IdType="pubmed">29641433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K., Min X., Lin Y., Huang Y., Huang S., Liu L., Peng Y., Meng K., Li D., Ji Q., et al. Increased IL-37 concentrations in patients with arterial calcification. Clin. Chim. Acta. 2016;461:19–24. doi: 10.1016/j.cca.2016.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.07.011</ArticleId><ArticleId IdType="pubmed">27451144</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Bautista F., Posadas-Sánchez R., Vázquez-Vázquez C., Fragoso J.M., Rodríguez-Pérez J.M., Vargas-Alarcón G. IL-37 Gene and Cholesterol Metabolism: Association of Polymorphisms with the Presence of Hypercholesterolemia and Cardiovascular Risk Factors. The GEA Mexican Study. Biomolecules. 2020;10:1409. doi: 10.3390/biom10101409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10101409</ArticleId><ArticleId IdType="pmc">PMC7601011</ArticleId><ArticleId IdType="pubmed">33028050</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin D., Naji D.H., Xia Y., Li S., Bai Y., Jiang G., Zhao Y., Wang X., Huang Y., Chen S., et al. Genomic Variant in IL-37 Confers A Significant Risk of Coronary Artery Disease. Sci. Rep. 2017;7:42175. doi: 10.1038/srep42175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42175</ArticleId><ArticleId IdType="pmc">PMC5299598</ArticleId><ArticleId IdType="pubmed">28181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Wang A., Jiang F., Hu J., Zhang X. Effects of interleukin-37 on cardiac function after myocardial infarction in mice. Int. J. Clin. Exp. Pathol. 2015;8:5247–5251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503097</ArticleId><ArticleId IdType="pubmed">26191225</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B., Meng K., Ji Q., Cheng M., Yu K., Zhao X., Tony H., Liu Y., Zhou Y., Chang C., et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin. Exp. Immunol. 2014;176:438–451. doi: 10.1111/cei.12284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12284</ArticleId><ArticleId IdType="pmc">PMC4008989</ArticleId><ArticleId IdType="pubmed">24527881</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H., Xiong Y., Zhang Y., Leng Y., Tao J., Li L., Qiu Z., Xia Z. Activation of NRF2/FPN1 pathway attenuates myocardial ischemia–reperfusion injury in diabetic rats by regulating iron homeostasis and ferroptosis. Cell Stress Chaperones. 2021;27:149–164. doi: 10.1007/s12192-022-01257-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-022-01257-1</ArticleId><ArticleId IdType="pmc">PMC8943074</ArticleId><ArticleId IdType="pubmed">35124772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru Y., Luo Y., Liu D., Huang Q., Zhou X., Linghu M., Luo X., Lv Z., Wu Y., Zhang H., et al. Iso-rhamnetin alleviates ferroptosis-mediated colitis by activating the NRF2/HO-1 pathway and chelating iron. Int. Immunopharmacol. 2024;135:112318. doi: 10.1016/j.intimp.2024.112318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2024.112318</ArticleId><ArticleId IdType="pubmed">38795598</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Chu W., Zhang H., Peng Y. Nrf2 and Ferroptosis: A New Research Direction for Ischemic Stroke. Cell. Mol. Neurobiol. 2023;43:3885–3896. doi: 10.1007/s10571-023-01411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-023-01411-y</ArticleId><ArticleId IdType="pmc">PMC11407729</ArticleId><ArticleId IdType="pubmed">37728817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>